Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer

✍ Scribed by Chengying Liu; Jun Liu; Xin Wang; Weidong Mao; Lian Jiang; Hua Ni; Mingcong Mo; Wei Wang

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 519 KB
• Volume: 104
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.21944

✦ Synopsis

Abstract

Introduction

The purpose of this study was to evaluate the value of nm23‐H1 and proliferating cell nuclear antigen (PCNA) expression as well as other confirmed prognostic factors in predicting the clinical outcome after definitive surgery of pathologic stage I non‐small cell lung cancer (NSCLC).

Methods

Four hundred fifty‐two consecutive and non‐selected patients who underwent definitive surgery for stage I NSCLC were included in this study. Formalin‐fixed paraffin‐embedded specimens were stained for nm23‐H1 and PCNA, the correlation between the staining and its clinicopathological parameters, and its prognostic power were analyzed statistically.

Results

Of the 452 patients studied, 320 cases (70.8%) were high expression for nm23‐H1. A total of 182 carcinomas (40.3%) were PCNA high expression tumors. PCNA expression correlated with serum CEA level (P < 0.001), and differentiation (P < 0.001). In univariate analysis by log‐rank test, serum CEA level, pT stage, differentiation, nm23‐H1 expression, and PCNA expression were significant prognostic factors (P = 0.037, 0.021, <0.001, 0.042, and 0.014, respectively). In multivariate analysis, pT stage and nm23‐H1 expression maintained its independent prognostic influence on overall survival (P = 0.041 and 0.003, respectively).

Conclusions

nm23‐H1 may be a good biomarker to be applied in clinic to predict the prognosis of patients with completely resected pathologic stage I NSCLC. J. Surg. Oncol. 2011;104:181–186. © 2011 Wiley‐Liss, Inc.